Related Experiment Video
Updated: Jun 18, 2025
07:28
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
40.6K
Solid Lipid Nanoparticles Loaded with Dexamethasone Palmitate for Pulmonary Inflammation Treatment by Nebulization
Hsin-Hung Chen1, Chen-Hsiang Sang2, Chang-Wei Chou2
1Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu 30013, Taiwan.
Pharmaceutics
|July 27, 2024
Summary
New solid lipid nanoparticles effectively deliver dexamethasone to the lungs, reducing inflammation in pneumonia models. This nanoplatform shows promise for treating childhood pneumonia with fewer side effects.
Area of Science:
- Nanotechnology
- Pharmacology
- Pediatric Medicine
Background:
- Pneumonia is a leading cause of death in children globally.
- Dexamethasone is effective against pulmonary inflammation but has systemic side effects.
- Current drug delivery systems for pneumonia are suboptimal.
Purpose of the Study:
- To develop and evaluate solid lipid nanoparticles (SLNs) encapsulating dexamethasone palmitate (DXMS-Pal-SLNs) for pneumonia treatment.
- To assess the anti-inflammatory potential and targeted delivery of DXMS-Pal-SLNs to alveolar macrophages.
- To investigate the efficacy and safety of nebulized DXMS-Pal-SLNs in preclinical models of pneumonia.
Main Methods:
- Formulation and characterization of DXMS-Pal-SLNs for high drug loading and stability.
- In vitro studies using alveolar macrophages to assess cytokine reduction (TNF-α, IL-6).
- In vivo experiments in mice with lipopolysaccharide-induced pneumonia, evaluating cytokine levels and lung tissue response after nebulized DXMS-Pal-SLN administration.
Main Results:
- DXMS-Pal-SLNs demonstrated high drug loading efficiency, low leakage, and excellent colloidal stability, suitable for nebulization.
- In vitro, DXMS-Pal-SLNs significantly reduced TNF-α and IL-6 secretions from alveolar macrophages.
- In vivo, nebulized DXMS-Pal-SLNs markedly decreased lung cytokine levels and controlled inflammation without adverse effects like pulmonary infiltration.
Conclusions:
- Nebulized DXMS-Pal-SLNs represent a promising nanoplatform for targeted anti-inflammatory therapy in pneumonia.
- This approach effectively reduces lung inflammation and cytokine levels associated with pneumonia.
- The study highlights the potential of DXMS-Pal-SLNs for safer and more effective pediatric pneumonia treatment.
Related Concept Videos
01:23Inhaled Medications
246
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
246
01:22Drug Delivery: Miscellaneous Routes
333
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
333
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
233
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
233
01:17Drugs Used in Lower Respiratory Disorders: Overview
386
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
386
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
264
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
264